NIFEDIPINE, 30mg, prolonged release tab.
Valid Article
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
NIFEDIPINE, prolonged-release
- Not in the WHO list of Essential Medicines 2025 (immediate-release only)
Therapeutic Action
Selective calcium channel blocker with vascular effect
Indications
Gestational and chronic hypertension in pregnant women when labetalol is not suitable or not available.
Instructions for use
The tablets should be swallowed whole with a glass of water, either with or without food.
The recommended initial dose is one 30 mg tablet once-daily, up to a maximum of 90 mg once-daily.
Prolonged-release nifedipine lowers blood pressure in a controlled, gradual manner, reducing risks for both the mother and the foetus. Compared with immediate-release nifedipine, it helps avoid sudden drops in blood pressure that may compromise uteroplacental blood flow.
Labetalol is considered as the first-line treatment for hypertension in pregnancy, with Nifedipine as the second alternative and methyldopa as the third due to more side effects and lower effectiveness.
Precautions for Use
Do not confuse with immediate-release nifedipine, uterine relaxant indicated in the threatened premature labour.
Storage
Below 25ºC - Protect from sunlight
![[DORALABE2T-] LABETALOL hydrochloride, 200mg, tab.](/web/image/product.template/572516/image_256/%5BDORALABE2T-%5D%20LABETALOL%20hydrochloride%2C%20200mg%2C%20tab.?unique=87e498c)
![[DORAMETY2T-] METHYLDOPA, 250mg, tab.](/web/image/product.template/572608/image_256/%5BDORAMETY2T-%5D%20METHYLDOPA%2C%20250mg%2C%20tab.?unique=87e498c)